Help
RSS
API
Feed
Maltego
Contact
Domain > www.processapharmaceuticals.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2022-02-23
3.225.74.242
(
ClassC
)
2023-12-20
54.225.202.48
(
ClassC
)
2024-07-12
44.209.57.54
(
ClassC
)
2025-11-17
50.18.202.67
(
ClassC
)
2025-11-20
54.176.137.25
(
ClassC
)
Port 443
HTTP/1.1 200 OKDate: Mon, 17 Nov 2025 22:50:39 GMTServer: ApacheX-Frame-Options: SAMEORIGINStrict-Transport-Security: max-age31536000;X-XSS-Protection: 1; modeblockX-Content-Type-Options: nosniffFeatu !DOCTYPE html>html langen> head> meta http-equivx-ua-compatible contentieedge> meta charsetutf-8> link relalternate typeapplication/rss+xml titleProcessa Pharmaceuticals, Inc. - Recent News hrefhttps://www.processapharmaceuticals.com/news-media/press-releases/rss /> title>Processa Pharmaceuticals, Inc. (PCSA)/title> link relcanonical hrefhttps://www.processapharmaceuticals.com>meta propertyog:url contenthttps://www.processapharmaceuticals.com>meta propertyog:site_name contentProcessa Pharmaceuticals, Inc.>meta propertyog:title contentProcessa Pharmaceuticals, Inc.>meta propertyog:type contentwebsite>meta propertyog:image contenthttps://d1io3yog0oux5.cloudfront.net/_034b146e49e70aa5f840ac62469a90a7/processapharmaceuticals/db/1102/9252/social_image_resized.jpg>meta nametwitter:card contentsummary_large_image>meta propertyog:description contentProcessa Pharmaceuticals is committed to developing drug products aimed at improving the quality of life for patients with unmet medical needs.>meta namedescription contentProcessa Pharmaceuticals is committed to developing drug products aimed at improving the quality of life for patients with unmet medical needs.>script typeapplication/ld+json> {@context:http://schema.org,@type:Corporation,name:Processa Pharmaceuticals, Inc.,address:{@type:PostalAddress,streetAddress:601 21st Street Suite 300,addressLocality:Vero Beach, FL,postalCode:32960,addressCountry:},legalName:Processa Pharmaceuticals, Inc.,description:The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobios
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]